Literature DB >> 22854592

Survival prognostic factors in patients with glioblastoma: our experience.

S Raysi Dehcordi1, D De Paulis, S Marzi, A Ricci, A Cimini, M G Cifone, R J Galzio.   

Abstract

AIM: Approximate survival for glioblastoma is less than 1 year. Age, histological features and performance status at presentation represent the three statistically independent factors affecting longevity. The purpose of the study was to assess the role of surgery and to analyze prognostic factors in our patients operated for glioblastoma.
METHODS: We evaluated in 56 patients operated for glioblastoma their depressive and performance status in the preoperative and postoperative time. Moreover we analyzed the extent of surgery, the site and the size of lesions.
RESULTS: Median overall survival was 17 months. An age of ≥60 years (P<0.03), a preoperative Karnofsky Performance Status KPS≤70 (P=0.04), a subtotal tumor resection (P<0.001), a tumor size >5 cm (P=0.01), and no postoperative adjuvant treatment (P=0.01) were associated with the worst prognosis. Before surgery we found the presence of depression in 10 patients with a significative reduction of mean Back Depression Inventory scores after tumor resection (P=0.03). Finally, a KPS≤70 was significantly associated with an increased incidence of depression in the postoperative time.
CONCLUSION: Tumor size, total resection and affective disorders were identified as predictors of survival in our series of patients with glioblastoma in addition to age and KPS score. In our opinion an early diagnosis and the use of specific safeguards in the operating room contribute to have an extension of the tumor progression time and median survival.

Entities:  

Mesh:

Year:  2012        PMID: 22854592

Source DB:  PubMed          Journal:  J Neurosurg Sci        ISSN: 0390-5616            Impact factor:   2.279


  13 in total

1.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.

Authors:  Susann Herzog; Matthias Alexander Fink; Kerstin Weitmann; Claudius Friedel; Stefan Hadlich; Sönke Langner; Katharina Kindermann; Tobias Holm; Andreas Böhm; Eskil Eskilsson; Hrvoje Miletic; Markus Hildner; Michael Fritsch; Silke Vogelgesang; Christoph Havemann; Christoph Alexander Ritter; Henriette Elisabeth Meyer zu Schwabedissen; Bernhard Rauch; Wolfgang Hoffmann; Heyo Klaus Kroemer; Henry Schroeder; Sandra Bien-Möller
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

2.  Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma.

Authors:  Shi-Yong Wang; Yi-Quan Ke; Guo-Hui Lu; Zhen-Hua Song; Li Yu; Sha Xiao; Xin-Lin Sun; Xiao-Dan Jiang; Zhi-Lin Yang; Chang-Chen Hu
Journal:  J Neurooncol       Date:  2013-02-16       Impact factor: 4.130

Review 3.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

Review 4.  The role of brachytherapy in the treatment of glioblastoma multiforme.

Authors:  Eric Barbarite; Justin T Sick; Emmanuel Berchmans; Amade Bregy; Ashish H Shah; Nagy Elsayyad; Ricardo J Komotar
Journal:  Neurosurg Rev       Date:  2016-05-16       Impact factor: 3.042

5.  Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.

Authors:  Lina Marenco-Hillembrand; Olindi Wijesekera; Paola Suarez-Meade; David Mampre; Christina Jackson; Jennifer Peterson; Daniel Trifiletti; Julie Hammack; Kyle Ortiz; Elizabeth Lesser; Matthew Spiegel; Calder Prevatt; Maria Hawayek; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana
Journal:  J Neurooncol       Date:  2020-03-09       Impact factor: 4.130

6.  BUB1 and BUBR1 inhibition decreases proliferation and colony formation, and enhances radiation sensitivity in pediatric glioblastoma cells.

Authors:  Andressa Gois Morales; Julia Alejandra Pezuk; María Sol Brassesco; Jaqueline Carvalho de Oliveira; Rosane Gomes de Paula Queiroz; Hélio Rubens Machado; Carlos Gilberto Carlotti; Luciano Neder; Harley Francisco de Oliveira; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2013-06-02       Impact factor: 1.475

7.  Changing the clinical course of glioma patients by preoperative motor mapping with navigated transcranial magnetic brain stimulation.

Authors:  Sandro M Krieg; Nico Sollmann; Thomas Obermueller; Jamil Sabih; Lucia Bulubas; Chiara Negwer; Tobias Moser; Doris Droese; Tobias Boeckh-Behrens; Florian Ringel; Bernhard Meyer
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430

Review 8.  Health-related quality of life and psychological functioning in patients with primary malignant brain tumors: a systematic review of clinical, demographic and mental health factors.

Authors:  Paul D Baker; Jacki Bambrough; John R E Fox; Simon D Kyle
Journal:  Neurooncol Pract       Date:  2015-10-23

9.  Impact of standard care on elderly glioblastoma patients.

Authors:  Sarah Lapointe; Marie Florescu; David Simonyan; Karine Michaud
Journal:  Neurooncol Pract       Date:  2016-12-09

Review 10.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.